Rosetta Working to Settle Dispute with US Marketing Partner Over Dx-Development Deal | GenomeWeb

By Doug Macron

Rosetta Genomics last week disclosed that it is currently negotiating with the US commercialization partner for its three microRNA-based cancer diagnostics over a funding dispute tied to the development of additional tests.

However, Rosetta was unable to provide guidance on the timing of a resolution to the matter, or if a resolution is imminent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.